{"id":"agmb-129","safety":{"commonSideEffects":[{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AGMB-129 works by binding to CD47, a protein that sends a 'do not eat' signal to macrophages, thereby inhibiting tumor cell evasion from the immune system.","oneSentence":"AGMB-129 is an anti-CD47 monoclonal antibody.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:21:11.966Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of various cancers"}]},"trialDetails":[{"nctId":"NCT05843578","phase":"PHASE2","title":"STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Agomab Spain S.L.U.","startDate":"2023-08-01","conditions":"Fibrostenotic Crohn's Disease","enrollment":103},{"nctId":"NCT07118878","phase":"PHASE1","title":"A Multiple Ascending Dose Study With AGMB-129 in Healthy Participants","status":"COMPLETED","sponsor":"Agomab Spain S.L.U.","startDate":"2025-08-06","conditions":"Fibrostenotic Crohn's Disease","enrollment":30},{"nctId":"NCT05937386","phase":"PHASE1","title":"Drug-Drug Interaction Study With AGMB-129 and Midazolam in Healthy Participants","status":"COMPLETED","sponsor":"Agomab Spain S.L.","startDate":"2023-08-09","conditions":"Healthy Volunteers","enrollment":14},{"nctId":"NCT06397508","phase":"PHASE1","title":"Relative Bioavailability and Effect of Food Study With AGMB-129 in Healthy Participants","status":"COMPLETED","sponsor":"Agomab Spain S.L.","startDate":"2024-04-02","conditions":"Healthy Volunteers","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AGMB-129","genericName":"AGMB-129","companyName":"Agomab Spain S.L.","companyId":"agomab-spain-s-l","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AGMB-129 is an anti-CD47 monoclonal antibody. Used for Treatment of various cancers.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}